Blood
Articles in this Issue
Ribosomal RNA methylation in HSCs: it's so “good for you”
Prothrombinase again, but different this time
A myeloma identity crisis yields daratumumab resistance
The proteasome: a gatekeeper stabilizing BCMA expression
Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy
Abstract In this response-adapted clinic trial with daratumumab monotherapy for older patients with newly diagnosed multiple myeloma (MM), we identified target antigen expression,...
Dynamic rRNA methylation regulates translation in the hematopoietic system and is essential for stem cell fitness
Abstract Self-renewal and differentiation are at the basis of hematopoiesis. Although it is known that tight regulation of translation is vital for hematopoietic stem cells’ (HSC)...
Menin inhibitors: a 2-in-1 defense versus AML immune evasion
Impact of <i>TP53</i> mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia
Abstract TP53 mutations are associated with unfavorable survival in many hematologic malignancies. However, the impact of TP53 mutations and their variant allele frequency (VAF) in...
Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML
Abstract Acute myeloid leukemia (AML) carrying chromosomal rearrangements involving the lysine methyltransferase 2A (KMT2A) gene frequently relapse after allogeneic hematopoietic c...
Primary colonic T-cell lymphoma with a TFH phenotype, favoring extranodal TFH lymphoma, angioimmunoblastic type
A 3.3-Å cryo-EM structure of an engineered high-affinity human prothrombinase complex
Abstract Thrombin is generated from prothrombin through cleavage at 2 sites by the enzyme prothrombinase, composed of factor Xa (fXa) and fVa. The affinity of fXa for fVa is low, w...
The post-BCMA playbook: RD118 GPRC5D CAR T cells for myeloma
Insights from single-cell omics: cellular heterogeneity as a foundation of clinical outcome in chronic myeloid leukemia
Abstract The BCR::ABL1 tyrosine kinase inhibitors (TKI) in chronic myeloid leukemia (CML) represent a paradigm for molecularly targeted therapy. However, clinical outcomes (rate/de...
The fully human anti-GPRC5D CAR T-cell therapy RD118 induces durable remissions in relapsed/refractory multiple myeloma
Abstract GPRC5D has emerged as a promising therapeutic target in relapsed/refractory multiple myeloma (R/R MM), particularly following progression after B-cell maturation antigen (...
Targeting proteostasis addiction in AML
The proteostasis network is a therapeutic target in acute myeloid leukemia
Abstract Oncogenic growth places great strain and dependence on protein homeostasis (proteostasis). This has made proteostasis pathways attractive therapeutic targets in cancer, bu...
Boosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens
Abstract Chimeric antigen receptor (CAR) T cells exhibit high response rates in B-cell malignancies, but most patients eventually relapse. A key mechanism of treatment failure is t...